Implications of Off-Label Use of Acetazolamide in the Management of Moyamoya Disease in Japan

Radiology - United States
doi 10.1148/radiol.2016152305
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Radiological Society of North America (RSNA)

Related search

Current Off-Label Pharmacotherapeutics in the Management of Novel Coronavirus Disease (COVID-19)

NeuroPharmac Journal
2020English

An Evaluation of the Cerebral Hemodynamics in Moyamoya Disease With Acetazolamide (Diamox) 99mTc-Hmpao SPECT.

RADIOISOTOPES
1994English

Off-Label Use of Omalizumab in Pediatric Anaphylaxis

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Off-Label Use of Approved Drugs

Nature Reviews Clinical Oncology
Oncology
2009English

Off-Label Use of Rituximab in Dermatology: Pemphigus Treatment

Anais Brasileiros de Dermatologia
Dermatology
2013English

Off-Label Use of Anticancer Drugs in South Korea

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Strategy to Address Innovative Off-Label Medication Use in China: Grading Management

European Journal of Clinical Pharmacology
MedicinePharmacology
2014English

Off-Label Drug Use in Hospitalized Children

Archives of Pediatrics & Adolescent Medicine
2007English

Off-Label Use in Lymphoma Patients in Switzerland

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy